Table 1.
Clinicopathological characteristics of patient and the correlation between SSTR2 expression and clinical and molecular pathological characteristics of patients with glioma
| Characteristics | Total (n = 302) | SSTR2 Low (≤ 4) expression (%) | SSTR2 high (≥ 6) expression (%) | chi-square test P value |
|---|---|---|---|---|
| Sex | 0.668 | |||
| male | 178 | 134 (75.28) | 44 (24.71) | |
| female | 124 | 96 (77.42) | 28 (22.58) | |
| Age (y) | 0.152 | |||
| < 55 | 233 | 173 (74.25) | 60 (25.75) | |
| ≥ 55 | 69 | 57 (82.61) | 12 (17.39) | |
| WHO grade | < 0.001 | |||
| I | 14 | 11 (78.57) | 3 (21.43) | |
| II | 81 | 43 (53.09) | 38 (46.91) | |
| III | 76 | 56 (73.68) | 20 (26.31) | |
| IV | 131 | 120 (91.60) | 11 (8.40) | |
| epilepsy | 0.001 | |||
| no | 219 | 178 (81.28) | 41 (18.72) | |
| yes | 83 | 52 (62.65) | 31 (37.35) | |
| Location | 0.037 | |||
| subtentorial | 17 | 17 (100) | 0 (0) | |
| supratentorial | 285 | 213 (74.73) | 72 (25.26) | |
| Ki-67 | < 0.001 | |||
| < 10% | 74 | 45 (60.81) | 29 (39.19) | |
| ≥ 10% | 228 | 185 (81.14) | 43 (18.86) | |
| P53 | 0.18 | |||
| < 10% | 110 | 79 (71.82) | 31 (28.18) | |
| ≥ 10% | 192 | 151 (78.65) | 41 (21.35) | |
| PHH3 | < 0.001 | |||
| < 5 | 122 | 77 (63.11) | 45 (36.89) | |
| ≥ 5 | 180 | 153 (85.00) | 27 (15.00) | |
| ATRX | 0.571 | |||
| positive | 159 | 119 (74.84) | 40 (25.16) | |
| negative | 143 | 111 (77.62) | 32 (22.38) | |
| IDH1 | < 0.001 | |||
| Wild-type | 176 | 156 (88.64) | 20 (11.36) | |
| Mutated | 126 | 74 (58.73) | 52 (41.27) | |
| 1p/19q | < 0.001 | |||
| non-codeleted | 254 | 204 (80.31) | 50 (19.69) | |
| codeleted | 48 | 26 (54.17) | 22 (45.83) | |
| MGMTp | 0.856 | |||
| methylated | 144 | 109 (75.69) | 35 (24.31) | |
| unmethylated | 158 | 121 (76.58) | 37 (23.42) | |
| TERTp | 0.262 | |||
| Mutated | 142 | 104 (73.24) | 38 (26.76) | |
| Wild-type | 160 | 126 (78.75) | 34 (21.25) | |